Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis

Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis

Multiorgan fibrosis in systemic sclerosis (SSc) accounts for substantial mortality and lacks effective therapies. Lying at the crossroad of TGF-β and TLR signaling, TGF-β–activated kinase 1 (TAK1) might have a pathogenic role in SSc. We therefore sought to evaluate the TAK1 signaling axis in patient...

Full description

Bibliographic Details
Main Authors: Swarna Bale, Priyanka Verma, Bharath Yalavarthi, Scott Arthur Scarneo, Philip Hughes, M. Asif Amin, Pei-Suen Tsou, Dinesh Khanna, Timothy A.J. Haystead, Swati Bhattacharyya, John Varga
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-07-01
Series:JCI Insight
Subjects:
Autoimmunity
Dermatology
Online Access:https://doi.org/10.1172/jci.insight.165358

Internet

https://doi.org/10.1172/jci.insight.165358

Similar Items